Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2011

View Archived Issues

Preclinical and clinical phase I/II data presented on GSK-573719 for COPD

Novel SMYD2 inhibitor identified at AstraZeneca

Novel pan-Aurora kinase inhibitor is active against drug-resistant cancer cells

Novel CO-releasing rhenium complexes developed at Swiss university

Phosphagenics to advance development of twice-weekly oxycodone patch

Enrollment complete in pediatric Xerecept trial

Incozen Therapeutics describes new PI3K-delta inhibitor

Creabilis raises funds for development of CT-327

Scientists at GSK prepare new lysophospholipid S1P1 receptor agonists

Novel neuroprotective agents patented

New saRNA molecules claimed by University of California scientists

Novel PP1 inhibitors synthesized

EntreMed reports encouraging phase II results on ENMD-2076

Fibrocell Science launches laViv in U.S.

InSite Vision releases phase II pharmacokinetic data on BromSite

Intellect Neurosciences and ViroPharma enter licensing agreement for OX-1

CalciMedica presents novel protein orai-1 inhibitors

NuPathe reports encouraging data from migraine patch trial

Gliknik receives SBIR contract to advance stradobodies

Merck Serono and Ono Pharmaceutical collaborate on MS drug and cancer vaccine

G-Zero Therapeutics receives NIH grant for studies in radiation exposure

Karo Bio enrolls first patient in AKKA study

Neurocrine and Abbott reach second milestone in elagolix collaboration

First patients dosed with Xiaflex in Dupuytren's contracture multicord study

Cariprazine study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...